Belgium Janssen has the lofty aim of reaching USD 60bn dollars in sales by 2025, an 8bn increase on the 2021 figure, despite some high-profile losses of exclusivity and the spin-off of its consumer healthcare branch. This massive growth plan involves both existing products as well as new CAR-T and autoimmune…
Belgium Maria Fernanda Prado highlights some of the lessons drawn from her extensive experience in emerging markets which remain applicable in her current role as Janssen’s managing director for the Benelux region. Belgium, the home country of Dr Paul Janssen, continues to be a significant part of the company’s global operations,…
China A roundup of some of the biggest pharma and biotech news from China including the collaboration between Elektr and Sinopharm; Biocytogen’s partnership with Janssen and deal with Chipscreen Biosciences; China’s first personalised neoantigen-targeted cancer vaccine approval; the final green light for Sino Biopharm’s purchase of F-star, and AstraZeneca’s deal with…
Greece Christian Rodseth, VP and managing director for Janssen’s Greece, Poland, and Romania cluster, outlines the multifaceted strengths of his teams, the part of the Janssen portfolio he is most excited to bring to the region, and the policy measures needed to ensure that Greek healthcare remains sustainable and able to…
Saudi Arabia Jamie Phares, Managing Director, Janssen, the Pharmaceutical Companies of Johnson & Johnson in the GCC, comments on the evolving approach to healthcare provision in the region, the role of Saudi Arabia in the regional healthcare market, and what the country needs to further develop its biopharma sector. In addition, she…
Denmark Julie Enevold Brooker discusses what she sees as Janssen’s responsibility to help improve the Danish healthcare system beyond just bringing innovative medicines to patients, gives her thoughts on the new Danish National Life Science Strategy, and outlines how Danish patients could have even better access to innovation. All stakeholders…
Turkey After an international career spanning 25 years, Demet Russ returned to her native Turkey to lead the Janssen affiliate during a tumultuous time and is aiming to give back to her country by improving patients’ access to life-saving therapies. For Russ, what began as a consultant role at McKinsey…
Turkey Janssen’s Managing Director for Turkey, Demet Russ, discusses her return to the country after 25 years abroad, having worked for Johnson & Johnson in different local, regional and global roles in Germany, Belgium, France and the US. She explains how Janssen Turkey’s vision “We are here for the better” is…
Europe Janssen’s Cyril Titeux highlights the commonalities and challenges within his 31-country portfolio, his hopes and expectations for the evolution of market access in the region, and some of the key industry trends emerging from the COVID-19 pandemic. I foresee a renewed and increased focus on prevention [post-COVID], especially for…
Global With several COVID-19 vaccines gaining regulatory approval across the world in record time, a spotlight has been shone on the vaccines field more widely, notably the 30-year wait for a HIV vaccine. Janssen Global Therapeutic Area Head of Vaccines Johan Van Hoof recently sat down with PharmaBoardroom to discuss the…
Global Dr Johan Van Hoof, global therapeutic area head of vaccines for Janssen, shares his extensive career experience in vaccines; the learnings from Janssen’s Ebola vaccine; and his key message to the global community on vaccines. We need to be sure we are not complacent. We have to keep an…
Norway Janssen Norway’s Mario Klesse shares his first impressions of the Norwegian pharma market, his strategic priorities for the affiliate, how Janssen is defining and meeting unmet patient needs, key access challenges, and the importance of bringing more clinical trials to Norway. We will only see the massive advantages of…
See our Cookie Privacy Policy Here